D.A. Davidson & Co. Incyte Corp Transaction History

D.A. Davidson & Co.

$12 Billion
Q3 2024

A detailed history of D.A. Davidson & Co. transactions in Incyte Corp stock. As of the latest transaction made, D.A. Davidson & Co. holds 3,225 shares of INCY stock, worth $224,556. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,225

Previous 3,475 7.19%

Holding current value

$224,556

Previous $210,000 1.43%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$57.33 - $68.61 $14,332 - $17,152	-250 Reduced 7.19%	3,225 $213,000
Q2 2024 Jul 31, 2024	SELL	$51.18 - $63.75 $51,180 - $63,750	-1,000 Reduced 22.35%	3,475 $210,000
Q1 2024 May 13, 2024	BUY	$56.55 - $66.59 $14,024 - $16,514	248 Added 5.87%	4,475 $254,000
Q4 2023 Feb 09, 2024	BUY	$52.16 - $64.19 $220,480 - $271,331	4,227 New	4,227 $265,000
Q2 2023 Aug 10, 2023	BUY	$60.95 - $75.51 $4,144 - $5,134	68 Added 2.06%	3,362 $209,000
Q1 2023 Apr 25, 2023	SELL	$70.23 - $86.01 $289,698 - $354,791	-4,125 Reduced 55.6%	3,294 $238,000
Q4 2022 Feb 03, 2023	BUY	$67.18 - $84.11 $278,326 - $348,467	4,143 Added 126.47%	7,419 $595,000
Q3 2022 Nov 07, 2022	BUY	$66.18 - $82.86 $7,676 - $9,611	116 Added 3.67%	3,276 $218,000
Q2 2022 Jul 28, 2022	SELL	$66.18 - $83.18 $9,265 - $11,645	-140 Reduced 4.24%	3,160 $240,000
Q1 2022 May 12, 2022	BUY	$66.02 - $79.71 $9,903 - $11,956	150 Added 4.76%	3,300 $262,000
Q4 2021 Jan 31, 2022	SELL	$63.34 - $74.11 $32,050 - $37,499	-506 Reduced 13.84%	3,150 $231,000
Q1 2021 May 07, 2021	SELL	$76.02 - $100.5 $7,145 - $9,447	-94 Reduced 2.51%	3,656 $297,000
Q4 2020 Feb 10, 2021	SELL	$80.74 - $97.7 $8,073 - $9,770	-100 Reduced 2.6%	3,750 $326,000
Q3 2020 Nov 02, 2020	SELL	$85.07 - $109.69 $36,835 - $47,495	-433 Reduced 10.11%	3,850 $345,000
Q2 2020 Aug 10, 2020	SELL	$74.18 - $108.93 $7,418 - $10,893	-100 Reduced 2.28%	4,283 $445,000
Q1 2020 May 05, 2020	SELL	$63.18 - $85.97 $16,426 - $22,352	-260 Reduced 5.6%	4,383 $321,000
Q4 2019 Feb 14, 2020	SELL	$73.04 - $95.72 $18,771 - $24,600	-257 Reduced 5.24%	4,643 $405,000
Q3 2019 Nov 05, 2019	SELL	$72.82 - $86.52 $89,204 - $105,987	-1,225 Reduced 20.0%	4,900 $364,000
Q2 2019 Aug 13, 2019	SELL	$73.52 - $88.7 $123,293 - $148,749	-1,677 Reduced 21.49%	6,125 $520,000
Q1 2019 May 13, 2019	BUY	$63.56 - $88.17 $444 - $617	7 Added 0.09%	7,802 $615,000
Q4 2018 Jan 29, 2019	SELL	$58.5 - $69.94 $79,560 - $95,118	-1,360 Reduced 14.86%	7,795 $496,000
Q3 2018 Nov 13, 2018	BUY	$61.75 - $74.23 $51,623 - $62,056	836 Added 10.05%	9,155 $632,000
Q2 2018 Aug 02, 2018	SELL	$60.85 - $83.98 $44,116 - $60,885	-725 Reduced 8.02%	8,319 $557,000
Q1 2018 May 04, 2018	SELL	$83.06 - $100.98 $10,880 - $13,228	-131 Reduced 1.43%	9,044 $754,000
Q4 2017 Feb 08, 2018	BUY	$93.56 - $116.6 $9,356 - $11,660	100 Added 1.1%	9,175 $869,000
Q3 2017 Nov 08, 2017	BUY	$109.15 - $138.27 $3,929 - $4,977	36 Added 0.4%	9,075 $1.06 Million
Q2 2017 Aug 11, 2017	BUY	N/A	9,039	9,039 $0

Others Institutions Holding INCY

# of Institutions

644

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

News

Stay updated on D.A. Davidson & Co. with notifications on news.

Account